Patents by Inventor Fude Huang

Fude Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240173287
    Abstract: The use of a genetic method to down-regulate RBO/EFR3/EFR3A/EFR3B proteins, TTC7 protein or PI4KIII? enzyme protein which interacts with RBO/EFR3/EFR3A/EFR3B proteins and TTC7 protein, or the use of a drug to inhibit PI4KIII? protein kinase activity reduces the accumulation of A?42 within neurons and age-dependent synaptic transmission failure and other obstacles in a fruit fly AD model, and obtains an effect of improving the learning and memory abilities of AD model mice. Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIII? inhibitor to treat Alzheimer's disease. Also provided is a method for screening a drug treating Alzheimer's disease by whether A? secretion by nerve cells is promoted or not.
    Type: Application
    Filed: September 18, 2023
    Publication date: May 30, 2024
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Le Zhang, Lixiang Jiang, Tong Zhu, Haiyan Liu, Yudong Zhou, Yang He, Wanguo Wei
  • Publication number: 20240050395
    Abstract: Disclosed are a deuterated oxophenylarsine, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing a pharmaceutically acceptable carrier and the deuterated oxophenylarsine. The deuterated oxophenylarsine can be used for treating and preventing cancers and related diseases.
    Type: Application
    Filed: March 31, 2021
    Publication date: February 15, 2024
    Inventors: Fude Huang, Wenan Wang, Feng Hong, Wanguo Wei, Jiangang Zhang, Changping Jiao, Luxiang Cao
  • Patent number: 11766420
    Abstract: The use of a genetic method to down-regulate RBO/EFR3/EFR3A/EFR3B proteins, TTC7 protein or PI4KIII? enzyme protein which interacts with RBO/EFR3/EFR3A/EFR3B proteins and TTC7 protein, or the use of a drug to inhibit PI4KIII? protein kinase activity reduces the accumulation of A?42 within neurons and age-dependent synaptic transmission failure and other obstacles in a fruit fly AD model, and obtains an effect of improving the learning and memory abilities of AD model mice. Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIII? inhibitor to treat Alzheimer's disease. Also provided is a method for screening a drug treating Alzheimer's disease by whether A? secretion by nerve cells is promoted or not.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: September 26, 2023
    Assignee: JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO. LTD.
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Le Zhang, Lixiang Jiang, Tong Zhu, Haiyan Liu, Yudong Zhou, Yang He, Wanguo Wei
  • Publication number: 20230115711
    Abstract: Disclosed is a pharmaceutical composition comprising a micromolecule PI4KIII? inhibitor and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a lipid. Also disclosed are a method for preparing the pharmaceutical composition, and a method for treating PI4KIII?-related diseases by using the pharmaceutical composition.
    Type: Application
    Filed: July 6, 2020
    Publication date: April 13, 2023
    Inventors: Fude HUANG, Feng WANG, Shu YANG, Changping JIAO, Xiaojun ZHOU
  • Publication number: 20220362203
    Abstract: Provided are an inhibitor of PI4KIII?/FAM126/TTC7 complex and a method that uses the inhibitor to prevent or treat mood disorders.
    Type: Application
    Filed: September 27, 2020
    Publication date: November 17, 2022
    Inventors: Fude HUANG, Wen'an WANG, Changping JIAO, Changde HUANG, Tide HUANG
  • Patent number: 11236378
    Abstract: Disclosed is the use of genetic means or a related inhibitor to inhibit and down-regulate the amount of PI4KIII? protein, RBO/EFR3/EFR3A/EFR3B membrane proteins, TTC7 protein and membrane protein complexes formed by said proteins, or related enzyme activity to promote A? secretion by neuronal cells, reduce A? accumulation within neurons, and thereby reduce AD model fruit fly and mouse nerve dysfunction.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: February 1, 2022
    Assignee: Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd.
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Haiyan Liu
  • Publication number: 20190314321
    Abstract: The use of a genetic method to down-regulate RBO/EFR3/EFR3A/EFR3B proteins, TTC7 protein or PI4KIII? enzyme protein which interacts with RBO/EFR3/EFR3A/EFR3B proteins and TTC7 protein, or the use of a drug to inhibit PI4KIII? protein kinase activity reduces the accumulation of A?42 within neurons and age-dependent synaptic transmission failure and other obstacles in a fruit fly AD model, and obtains an effect of improving the learning and memory abilities of AD model mice. Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIII? inhibitor to treat Alzheimer's disease. Also provided is a method for screening a drug treating Alzheimer's disease by whether A? secretion by nerve cells is promoted or not.
    Type: Application
    Filed: May 3, 2016
    Publication date: October 17, 2019
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Le Zhang, Lixiang Jiang, Tong Zhu, Haiyan Liu, Yudong Zhou, Yang He, Wanguo Wei
  • Publication number: 20190211371
    Abstract: Disclosed is the use of genetic means or a related inhibitor to inhibit and down-regulate the amount of PI4KIII? protein, RBO/EFR3/EFR3A/EFR3B membrane proteins, TTC7 protein and membrane protein complexes formed by said proteins, or related enzyme activity to promote A? secretion by neuronal cells, reduce A? accumulation within neurons, and thereby reduce AD model fruit fly and mouse nerve dysfunction.
    Type: Application
    Filed: April 30, 2015
    Publication date: July 11, 2019
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Haiyan Liu